CUV 2.00% $14.81 clinuvel pharmaceuticals limited

1. adopt the 2024 Remuneration Report as part of the Financial...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 915 Posts.
    lightbulb Created with Sketch. 247
    1. adopt the 2024 Remuneration Report as part of the Financial Year ended 30 June 2024; Against (protest against high remuneration and glacial product development and poor trial reporting)

    2. elect Mr Matthew Pringle, as a Non-Executive Director of the Company; For

    3. elect Mr Guy van Dievoet, as a Non-Executive Director of the Company; For

    4. elect Dr Pearl Grimes, as a Non-Executive Director of the Company; For

    5. re-elect Mrs Susan Smith, as a Non-Executive Director of the Company; For

    6. re-elect Dr Karen Agersborg, as a Non-Executive Director of the Company; Against (protest against perceived puppet board)

    7. approve an increase in the Non-Executive Directors’ remuneration pool; For

    8. consider, if necessary, a conditional spill resolution. Against (don't need a spill, the ramifications will cause more harm to shareholders and will play into shorters' hands)
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.